Exact Sciences Corporation (EXAS)
- Previous Close
60.96 - Open
61.31 - Bid 62.38 x 400
- Ask 62.45 x 400
- Day's Range
60.68 - 63.23 - 52 Week Range
56.05 - 100.77 - Volume
1,466,085 - Avg. Volume
2,445,920 - Market Cap (intraday)
11.329B - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
-- - EPS (TTM)
-1.13 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
90.66
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
www.exactsciences.com6,500
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: EXAS
Performance Overview: EXAS
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EXAS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EXAS
Valuation Measures
Market Cap
11.33B
Enterprise Value
13.11B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.50
Price/Book (mrq)
3.60
Enterprise Value/Revenue
5.25
Enterprise Value/EBITDA
447.76
Financial Highlights
Profitability and Income Statement
Profit Margin
-8.17%
Return on Assets (ttm)
-3.04%
Return on Equity (ttm)
-6.60%
Revenue (ttm)
2.5B
Net Income Avi to Common (ttm)
-204.15M
Diluted EPS (ttm)
-1.13
Balance Sheet and Cash Flow
Total Cash (mrq)
777.64M
Total Debt/Equity (mrq)
81.60%
Levered Free Cash Flow (ttm)
91.77M
Research Analysis: EXAS
Company Insights: EXAS
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: EXAS
Analyst Report: Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
RatingPrice TargetAnalyst Report: Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
RatingPrice TargetAnalyst Report: Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
RatingPrice TargetAnalyst Report: Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
RatingPrice Target